William J. Catalona, MD, on Genetic Testing in Prostate Cancer: Expert Review

December 04, 2023 By The ASCO Post Staff

William J. Catalona, MD, of Northwestern University Feinberg School of Medicine, reviews the genetic landscape in prostate cancer, including BRCA2 and ATM, two important mutations for aggressive disease; the clinical implications of germline testing such as guiding screening and disease management, as well as identifying patients at high risk for aggressive prostate cancer; and the role of somatic testing, especially in advanced disease.

Related Content